ISIS Pharmaceuticals, Inc. (ISIS) Maintains A Buy Rating

Analysts Mark Monane, and Alan Carr at Needham have release an update on ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS).

The company along with its partner Genzyme Corporation (NASDAQ: GENZ) reported top-line results for Phase 3 mipomersen trial in patients with heterozygous familial hypercholesterolemia already on lipid-lowering agents.

According to analysts, the efficacy results from the trial are clinically meaningful. Analysts at Needham have reiterated a Buy rating for ISIS Pharmaceuticals, Inc., with a 12-month price target of $22.

According to analysts, ISIS’s net cash position, high-quality collaborations with big brand names in Pharma, and upcoming pipeline events are additional resources beyond mipomersen at the company.